BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38850724)

  • 41. Controlling nutritional status score as a new indicator of overt hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt.
    Li J; Feng D; Pang N; Zhao C; Gao L; Liu S; Li L
    Clin Nutr; 2022 Feb; 41(2):560-566. PubMed ID: 35032860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transjugular intrahepatic portosystemic shunt (TIPS) placement at index portal hypertensive decompensation (anticipant TIPS) in cirrhosis and the role of early intervention in variceal bleeding and ascites.
    Rajesh S; Philips CA; Betgeri SS; George T; Ahamed R; Mohanan M; Augustine P
    Indian J Gastroenterol; 2021 Aug; 40(4):361-372. PubMed ID: 34324168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.
    Nolte W; Wiltfang J; Schindler C; Münke H; Unterberg K; Zumhasch U; Figulla HR; Werner G; Hartmann H; Ramadori G
    Hepatology; 1998 Nov; 28(5):1215-25. PubMed ID: 9794904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients.
    Qi X; Han G; Yin Z; He C; Wang J; Guo W; Niu J; Zhang W; Bai M; Fan D
    Dig Dis Sci; 2012 Apr; 57(4):1072-82. PubMed ID: 22147244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation.
    Trivedi S; Lam K; Ganesh A; Hasnain Y; Hassan W; Herren J; Gaba RC
    Semin Intervent Radiol; 2023 Feb; 40(1):9-14. PubMed ID: 37152788
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elective Transjugular Intrahepatic Portosystemic Shunt Using Viatorr Stent-Grafts: A Single-Center Experience from China.
    Li YH; Wan YM; Wu HM; Huang SQ
    J Belg Soc Radiol; 2022; 106(1):62. PubMed ID: 35854822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients.
    Gou X; Jia W; He C; Yuan X; Niu J; Xu J; Han N; Zhu Y; Wang W; Tie J
    Eur Radiol; 2023 May; 33(5):3407-3415. PubMed ID: 36576548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
    Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
    World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
    Bureau C; Thabut D; Jezequel C; Archambeaud I; D'Alteroche L; Dharancy S; Borentain P; Oberti F; Plessier A; De Ledinghen V; Ganne-Carrié N; Carbonell N; Rousseau V; Sommet A; Péron JM; Vinel JP
    Ann Intern Med; 2021 May; 174(5):633-640. PubMed ID: 33524293
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High Incidence of Hepatic Encephalopathy After Viatorr Controlled Expansion Transjugular Intrahepatic Portosystemic Shunt Creation.
    Kloster ML; Ren A; Shah KY; Alqadi MM; Bui JT; Lipnik AJ; Niemeyer MM; Ray CE; Gaba RC
    Dig Dis Sci; 2021 Nov; 66(11):4058-4062. PubMed ID: 33236314
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosis.
    He C; Lv Y; Wang Z; Guo W; Tie J; Li K; Niu J; Zuo L; Yu T; Yuan X; Chen H; Wang Q; Liu H; Bai W; Wang E; Xia D; Luo B; Li X; Yuan J; Han N; Zhu Y; Wang J; Yin Z; Fan D; Han G
    Dig Liver Dis; 2018 Dec; 50(12):1315-1323. PubMed ID: 29960900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of transjugular intrahepatic portosystemic with endoscopic treatment plus anticoagulation for esophageal variceal bleeding and portal vein thrombosis in liver cirrhosis.
    Wu W; Zhang H; Zeng Z; Wang X; Kong D
    Scand J Gastroenterol; 2022 Dec; 57(12):1494-1502. PubMed ID: 35802771
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial).
    de Wit K; Schaapman JJ; Nevens F; Verbeek J; Coenen S; Cuperus FJC; Kramer M; Tjwa ETTL; Mostafavi N; Dijkgraaf MGW; van Delden OM; Beuers UHW; Coenraad MJ; Takkenberg RB
    BMJ Open Gastroenterol; 2020 Dec; 7(1):. PubMed ID: 33372103
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.
    Ferrusquía-Acosta J; Bassegoda O; Turco L; Reverter E; Pellone M; Bianchini M; Pérez-Campuzano V; Ripoll E; García-Criado Á; Graupera I; García-Pagán JC; Schepis F; Senzolo M; Hernández-Gea V
    J Hepatol; 2021 Apr; 74(4):811-818. PubMed ID: 33068638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation between hepatic venous pressure gradient and portal venous pressure gradient in hepatitis B cirrhosis with different hepatic veins anatomy.
    Lv Y; Song Q; Yue Z; Zhao H; Wang L; Fan Z; Wu Y; Meng M; Zhang K; Jiang L; Ding H; Zhang Y; Liu F
    Eur J Radiol; 2022 Oct; 155():110463. PubMed ID: 35952477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel nomogram predicting overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in portal hypertension patients.
    Liao Y; Zhang L; Wang JT; Yue ZD; Fan ZH; Wu YF; Zhang Y; Dong CB; Wang XQ; Cui T; Meng MM; Bao L; Chen SB; Liu FQ; Wang L
    Sci Rep; 2023 Sep; 13(1):15244. PubMed ID: 37709823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension: prospective long-term results.
    Hermie L; Biervliet SV; Hoorens A; Cauwenberghe LV; Robberecht E; Defreyne L
    Diagn Interv Radiol; 2024 Jan; 30(1):55-64. PubMed ID: 36994654
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy: Sarcopenia Adds Insult to Injury.
    Bhatia Kapoor P; Benjamin J; Tripathi H; Patidar Y; Maiwall R; Kumar G; Joshi YK; Sarin SK
    Turk J Gastroenterol; 2023 Apr; 34(4):406-412. PubMed ID: 36620928
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Yang C; Liu J; Shi Q; Huang S; Zhou C; Wang Y; Li T; Chen Y; Xiong B
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2893-2902. PubMed ID: 33973270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predicting disease progression in cirrhotic patients after transjugular intrahepatic portosystemic shunt implantation: A sex-stratified analysis.
    Zhang Q; Long L; Zhu HL; Peng H; Luo XH; Zhu KS; Wang RP
    World J Gastroenterol; 2023 Nov; 29(42):5768-5780. PubMed ID: 38075849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.